Idioma:

Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma

FRIEDMAN, H. S ; PETROS, W. P ; CLOUGHSEY, T ; STEWART, E. S ; COLVIN, O. M ; PROVENZALE, J. M ; MCLENDON, R. E ; BIGNER, D. D ; COKGOR, L ; HAGLUND, M ; RICH, J ; ASHLEY, D ; FRIEDMAN, A. H ; MALCZYN, J ; ELFRING, G. L ; MILLER, L. L ; SCHAAF, L. J ; KERBY, T ; LAWYER, J ; PARRY, M ; HOUGHTON, P. J ; LOVELL, S ; RASHEED, K

Journal of clinical oncology, 1999-05, Vol.17 (5), p.1516-1525 [Periódico revisado por pares]

Baltimore, MD: American Society of Clinical Oncology

Sem texto completo

Citações Citado por

Enviar para

Título:
Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma
Autor: FRIEDMAN, H. S ; PETROS, W. P ; CLOUGHSEY, T ; STEWART, E. S ; COLVIN, O. M ; PROVENZALE, J. M ; MCLENDON, R. E ; BIGNER, D. D ; COKGOR, L ; HAGLUND, M ; RICH, J ; ASHLEY, D ; FRIEDMAN, A. H ; MALCZYN, J ; ELFRING, G. L ; MILLER, L. L ; SCHAAF, L. J ; KERBY, T ; LAWYER, J ; PARRY, M ; HOUGHTON, P. J ; LOVELL, S ; RASHEED, K
Assuntos: Adult ; Aged ; Antineoplastic agents ; Antineoplastic Agents, Phytogenic - pharmacokinetics ; Antineoplastic Agents, Phytogenic - therapeutic use ; Astrocytoma - blood ; Astrocytoma - drug therapy ; Biological and medical sciences ; Brain Neoplasms - blood ; Brain Neoplasms - drug therapy ; Camptothecin - analogs & derivatives ; Camptothecin - pharmacokinetics ; Camptothecin - therapeutic use ; Chemotherapy ; Disease Progression ; Female ; Glioblastoma - blood ; Glioblastoma - drug therapy ; Glioma - blood ; Glioma - drug therapy ; Humans ; Male ; Medical sciences ; Middle Aged ; Neoplasm Recurrence, Local - blood ; Neoplasm Recurrence, Local - drug therapy ; Oligodendroglioma - blood ; Oligodendroglioma - drug therapy ; Pharmacology. Drug treatments
É parte de: Journal of clinical oncology, 1999-05, Vol.17 (5), p.1516-1525
Descrição: To determine the activity, toxicity, and pharmacokinetics of irinotecan (CPT-11, Camptosar; Pharmacia & Upjohn, Kalamazoo, MI) in the treatment of adults with progressive, persistent, or recurrent malignant glioma. Patients with progressive or recurrent malignant gliomas were enrolled onto this study between October 1996 and August 1997. CPT-11 was given as a 90-minute intravenous (i.v.) infusion at a dose of 125 mg/m2 once weekly for 4 weeks followed by a 2-week rest, which comprised one course. Plasma concentrations of CPT-11 and its metabolites, SN-38 and SN-38 glucuronide (SN-38G), were determined in a subset of patients. All 60 patients who enrolled (36 males and 24 females) were treated with CPT-11 and all were assessable for toxicity, response, and survival. Pharmacokinetic data were available in 32 patients. Nine patients (15%; 95% confidence interval, 6% to 24%) had a confirmed partial response, and 33 patients (55%) achieved stable disease lasting more than two courses (12 weeks). Toxicity observed during the study was limited to infrequent neutropenia, nausea, vomiting, and diarrhea. CPT-11, SN-38, and SN-38G area under the plasma concentration-time curves through infinite time values in these patients were approximately 40%, 25%, and 25%, respectively, of those determined previously in patients with metastatic colorectal cancer not receiving antiepileptics or chronic dexamethasone treatment. Response results document that CPT-11, given with a standard starting dose and treatment schedule, has activity in patients with recurrent malignant glioma. However, the low incidence of severe toxicity and low plasma concentrations of CPT-11 and SN-38 achieved in this patient population suggest that concurrent treatment with anticonvulsants and dexamethasone enhances drug clearance.
Editor: Baltimore, MD: American Society of Clinical Oncology
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma

Baltimore, MD: American Society of Clinical Oncology

Buscando em bases de dados remotas. Favor aguardar.